New York – New York
Bayer is Bullish on Xarelto despite MDL’s growing in America according to this Reuters article. Claims were circulating that the drug maker was losing market share to Eliquis but the contrary is being claimed by Bayer. It actually raised its forecast of growth to 30 percent form 20.
All this growth forecast despite MDL’s in Louisiana and Pennsylvania. Xarelto was first advertised to the market as being a simple alternative to similar drugs already on the market. Claiming that less dietary restrictions and blood monitoring were required, once it hit the market Xarelto was linked to serious side effects. Those included gastrointestinal bleeding and about 65 death cases.1 The MDL is still very much in the beginning stages but many claimants and attorneys representing them are hopeful that a settlement will come in the next few years.
If you or someone you know has taken Xarelto and need financing for medical care, please contact Case Funding to see your eligibility for pre-settlement financing. To find out more about what Case Funding offers please call us at (800) 543-4043.
Approximately 9000 claimants breathed a sigh relief this past week. Takeda, the Japanese pharmaceutical giant agreed to settle approximately 9000 cases for a total of $2.4 billion. This translates roughly to $267,000 per case. The decline of use and eventual … Continue reading
New York- New York- The New York Times recently published an article titled “Junk Science at the F.B.I”, it discusses the apparently pseudoscientific practice of hair sample analysis. What is hair sample analysis? It is the practice of analyzing hair … Continue reading
New York, New York – Football has been played professionally since 1892, starting when William Heffelfinger was paid $500 to play in a single game. This payment began the era of professional football and later lead to the formation of an actual … Continue reading